Under the terms of the transaction, Malin has invested $20 million in Poseida with a commitment to invest a further $10 million next year subject to the achievement of certain milestones

Malin, the Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, is to take a 31 per cent (...)

Joe Papa CEO and president of Perrigo which is battling to escape the attentiions of rival Mylan. Photograph: Brenda Fitzsimons / The Irish Times

Top executives of Dublin-based over-the-counter drug company Perrigo arrived in Israel today for meetings with investors as they seek to fend off a ho(...)

Malin has  invested in 14 businesses

Listed life sciences investment group Malin has reported its maiden set of results. Excluding the costs of establishing the company, Malin reported a (...)

Joe Papa, chief executive  and president of Perrigo. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Irish over-the-counter drug company Perrigo has filed a lawsuit against suitor Mylan in a Manhattan court. The legal action comes as Perrigo urged its(...)

Robert Coury, executive chairman of Mylan pharmaceutical company with Taoiseach Enda Kenny at  a Galway and Dublin jobs announcement in 2012. Photograph: Alan Betson / The Irish Times

Shareholders in over-the-counter drug specialists Perrigo receive their latest quarterly dividend today. It comes as they mull the formal offer for th(...)

Former Elan boss Kelly Martin to take over as chief executive of Malin. Photo: Brenda Fitzsimons/The Irish Times

Irish life sciences investment firm Malin completed its initial series of asset purchases with two more investments on Monday and said director and fo(...)

Richard Pops, chief executive  of Alkermes at their Dublin offices. Photograph: Aidan Crawley

Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)

Joe Papa CEO and president of Perrigo, which has rejected a $29 billion bid from rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

AIB is a significant provider of seed capital funding in Ireland. It has committed €90 million to six funds, which have a combined size of €343 million

AIB has committed €15 million to a dedicated life-sciences venture-capital fund managed by Dublin-based Fountain Healthcare Partners. AIB is investing(...)

A generic form of the drug Plavix sits on crates at a Mylan Pharmaceuticals distribution centre in North Carolina.  Mylan has offered to acquire Perrigo for about $29 billion in what would be the latest mega-merger among drug makers if it is completed. Photograph: Travis Dove/The New York Times

Drugmaker Mylan offered to buy rival Perrigo for $28.9 billion in a deal that would create a powerhouse for generic medicine. Mylan, which makes abo(...)